ZIOPHARM Oncology (NASDAQ:ZIOP) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Thursday.

Several other analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.50 price target on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Friday, November 10th. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, Raymond James Financial reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $12.67.

ZIOPHARM Oncology (NASDAQ:ZIOP) traded up $0.13 during trading hours on Thursday, hitting $4.26. The company’s stock had a trading volume of 1,839,500 shares, compared to its average volume of 1,760,000. ZIOPHARM Oncology has a 1 year low of $3.77 and a 1 year high of $7.88. The stock has a market cap of $604.76, a PE ratio of -8.19 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the previous year, the business earned ($0.11) EPS. The business’s revenue was up .0% on a year-over-year basis. equities analysts forecast that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of the stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,924 shares in the last quarter. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $104,000. Oppenheimer & Co. Inc. raised its holdings in shares of ZIOPHARM Oncology by 50.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 6,000 shares in the last quarter. Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $141,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $145,000. 40.23% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology (ZIOP) Downgraded by BidaskClub” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/11/ziopharm-oncology-ziop-downgraded-by-bidaskclub.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.